novo semaglutide alzheimer's Nordisk shares slide after Ozempic pill fails in trials | Pharmaceuticals industry Could diabetes and weight loss

Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity. The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater. Semaglutide and Its Impact on Weight Loss Several studies have been published looking at the effects of Semaglutide injections on weight loss: Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity This study which was published in 2022 looked at the effects of Semaglutide weekly 1.7-mg or 2.4-mg subcutaneous injections for 3 to 6 months

That broad profile is part of its appeal, but it is also what makes careful interpretation essential

At the same time, it shows one piece of the bigger debate on whether societal investment in obesity treatment pays off

Until more is known, doctors recommend that women stop Ozempic when they begin trying to get pregnant and stay off it through pregnancy and breastfeeding